Detection of Mycoplasma pneumoniae Nucleic Acid and Drug Resistance Gene

Summary

This protocol provides a quick and reliable way to detect Mycoplasma pneumoniae infections and identify antibiotic resistance. It helps practitioners choose the right treatments faster, improving care for patients with pneumonia and supporting better use of antibiotics

Abstract

Mycoplasma pneumoniae (Mp) represents one of the most prevalent pathogens responsible for community-acquired pneumonia (CAP) in pediatric populations. The detection of Mycoplasma pneumoniae resistance genes provides robust technical support and a theoretical foundation for the precise clinical diagnosis and treatment of MP infections. Accurate diagnosis and evaluation of drug resistance in Mp infection are essential for clinical treatment. Common detection methods for Mycoplasma pneumoniae include culture, antibody detection, and molecular biology-based assays. Mp culture is the gold standard for diagnosis but requires a specific medium, is time-consuming, and has low sensitivity. Antibody-based detection of Mp is widely used; however, false negatives may occur in the early stage of infection. Molecular biology-based detection provides rapid turnaround, low risk of contamination, high sensitivity, high specificity, and is not limited by the timing of sample collection or immune status. It has therefore been recognized as a new gold standard for diagnosing Mycoplasma pneumoniae infection. Macrolide agents are the first-choice treatment for Mp infection in children. However, with the extensive use of macrolides in respiratory tract infections in children, the incidence of drug-resistant Mycoplasma pneumoniae infection has been increasing. Patients infected with resistant strains experience significantly longer fever duration, extended hospitalization, and prolonged fever after administration compared with those infected with sensitive strains. Mutation sites identified to date include 2063, 2064, 2067, and 2617. In China, point mutations have been documented only at positions 2063 and 2064, with an A-to-G substitution at position 2063 being the most common. For these sites, polymerase chain reaction (PCR) combined with fluorescent probe technology has been employed to detect the nucleic acids and drug resistance mutations of Mycoplasma pneumoniae in human sputum samples. Detection of Mycoplasma pneumoniae resistance genes offers crucial technical support and a theoretical basis for accurate diagnosis and effective treatment of Mp infection.

Introduction

Mycoplasma pneumoniae (Mp) is the smallest pathogenic microorganism capable of independent survival, situated at an intermediary position between bacteria and viruses. It is chiefly disseminated by respiratory droplets or aerosols and constitutes the second most common pathogen associated with community-acquired pneumonia (CAP) in children¹, responsible for 20% to 40% of CAP instances². Mp shows inherent resistance to β-lactam antibiotics, such as penicillin and cephalosporins, due to its absence of a cell wall, which these antibiotics target by obstructing cell wall synthesis. The principal therapeutic mod....

Protocol

All study protocols were reviewed and approved by the Medical Ethics Committee of Heyuan People's Hospital (Approval No. YXYJLL-LW2025001). All patients provided written informed consent prior to participation.

1. Specimen collection

NOTE: Exercise caution in maintaining aseptic technique during sample collection.

1. Collect specimens of sputum of the patient or suspected patient. Obtain samples within 3 days of the patient's disease onset.
2. Instruct the patient to rinse his mouth with water, breathe deeply, retain his breath for 5 s, and exhale gradually.
3. Ask the patient to ex....

Results

Following liquefaction, nucleic acid extraction, and fluorescence PCR amplification of sputum samples, the Start value, End value, and Threshold value of the baseline were modified after the analysis of the amplification curve. The Start value was 3, and the End value was 20.

The representative results of this experiment were positive for Mp nucleic acid, and an A : G resistance mutation occurred at 2063 or 2064 sites, suggestin.......

Discussion

PCR and its derivative techniques demonstrate superior sensitivity and specificity compared to serological methods in the identification, typing, and detection of drug resistance in Mycoplasma pneumoniae (MP). Moreover, PCR-based techniques provide ease of operation and reduced expenses, rendering them a viable alternative for routine clinical diagnostics³⁶. Mp is a notable pathogen associated with CAP and demonstrates a considerable prevalence³⁷. Choosing suitable.......

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
Automated nucleic acid extraction instrument	Guangzhou Da 'an Gene Co., Ltd.	Smart 32
Filter Tips	Coring Life Science Co., Ltd.	29822001	0-10µL
Filter Tips	Coring Life Science Co., Ltd.	03023001	1-50µL
Filter Tips	Coring Life Science Co., Ltd.	05623001	5-300µL
Microtubes	Coring Life Science Co., Ltd.	14124934	1.5mL
Mycoplasma pneumoniae nucleic acid and drug resistance mutation site detection kit ( fluorescence PCR method )	Jiangsu Mole Biotechnology Co., Ltd.	20241111
Nuclear acids extracting reagent(magnetic beads method)	Shengxiang Biotechnology Co., Ltd.	G24004
PCR tubes	DN Biotech(Hong Kong)  Co., Ltd.	6121003	0.2mL
Real-time fluorescent PCR instrument	BIO-RAD	CFX96